Included in the formulation
АТХ:J.07.B.C.02 Hepatitis A virus - purified antigen
Pharmacodynamics:The vaccine is a mixture of inactivated purified virions adsorbed on aluminum hydroxide. Promotes the formation of immunity against the hepatitis A virus, causing the production of specific antibodies. The number of antibodies that appear after the use of the vaccine is practically the same as the number of antibodies to the hepatitis A virus in people who have undergone this disease. In most patients, antibodies circulate in the blood for at least 1 year after the initial course of vaccination.
Pharmacokinetics:No data.
Indications:Active prophylaxis in people with an increased risk of hepatitis A (including in an epidemic).
XXI.Z20-Z29.Z24.6 The need for immunization against viral hepatitis
Contraindications:Acute infectious and non-infectious diseases, exacerbations of chronic diseases, immunodeficiency, malignant blood diseases and neoplasms, hypersensitivity to vaccine components, pregnancy, lactation (breastfeeding).
Carefully:They are used with caution in patients with thrombocytopenia and a tendency to hemorrhage, which is associated with an increased risk of developing a hematoma at the site of administration. Do not inject intravenously, subcutaneously, intradermally. Patients on hemodialysis and patients with impaired immunity require the introduction of additional doses of the vaccine.
Pregnancy and lactation:In pregnancy, vaccination is not recommended and is only possible in cases of emergency. If you need to use the drug during lactation, you should decide whether to stop breastfeeding.
Dosing and Administration:Individual. A single dose depends on the age and is 0.5-1 ml intramuscularly in the deltoid region of the muscle. The vaccination schedule and the timing of the revaccination depend on the drug formulation used.
Side effects:Maybe: headache, malaise, fatigue, fever, nausea, loss of appetite; hyperemia, compaction, swelling, tenderness at the injection site.
Rarely: anaphylactic and anaphylactoid reactions.
Overdose:There is no evidence of an overdose of the vaccine.
Interaction:The vaccine can be administered concomitantly with immunoglobulins, provided different parts of the body are used to inject the vaccine and immunoglobulins. Since this vaccine is inactivated, combining it with other inactivated vaccines does not affect the effectiveness of vaccination when vaccines are introduced into various parts of the body (in particular, with a recombinant vaccine for the prevention of hepatitis B, typhoid vaccine, live vaccine for the prevention of yellow fever). The vaccine can be used for revaccination and in those cases when the previous vaccination was carried out by other inactivated vaccines for the prevention of hepatitis A.
Special instructions:In children, the vaccine should be used only in the form of dosage forms specially designed for them.
Compliance with the recommended vaccine against hepatitis A should be strictly observed.